SCHEMBL759098

SCHEMBL759098

Cc1ccccc1C(=O)Nc1ccn(Cc2ccccc2C(F)(F)F)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.54
STIM1 Q13586 2/20 0.53
ORAI1 Q96D31 2/20 0.53
ORAI3 Q9BRQ5 1/20 0.53
LMNA P02545 3/20 0.52
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
APP P05067 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
SNCA P37840 1/20 0.51
HTT P42858 1/20 0.51
CACNA1G O43497 2/20 0.50
CACNA1H O95180 2/20 0.50
CACNA1I Q9P0X4 2/20 0.50
KMT2A Q03164 1/20 0.50
KDM4E B2RXH2 3/20 0.49
RIPK1 Q13546 2/20 0.49
ALDH1A1 P00352 4/20 0.48
GAA P10253 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756325 0.88 LMNA (0.49) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL757550 0.88 STIM1 (0.55) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL758395 0.88 STIM1 (0.55) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL757136 0.88 STIM1 (0.62) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL757450 0.87 STIM1 (0.53) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL760682 0.86 STIM1 (0.54) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL755899 0.85 STIM1 (0.74) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL759982 0.85 STIM1 (0.52) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL757152 0.85 STIM1 (0.52) NPSR1STIM1ORAI1ORAI3LMNA
SCHEMBL756222 0.85 STIM1 (0.58) NPSR1STIM1ORAI1ORAI3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399436-B2 N-pyrazolyl carboxamides as CRAC channel inhibitors GLAXO GROUP LIMITED (GB) 2013-03-19 US disclosed
US-8399436-B2 N-pyrazolyl carboxamides as CRAC channel inhibitors GLAXO GROUP LIMITED (GB) 2013-03-19 US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 US disclosed
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-01 US disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053150-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS ORAI1, TRPV1, CACNA1E NPSR1 1293/4885STIM1 33/4885ORAI1 1/4885
US-20100273744-A1 COMPOUNDS LTC4S, HRH4, HRH2 NPSR1 1288/4885STIM1 2564/4885ORAI1 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.